Neurizon Therapeutics Limited · ASX:NUZ
Neurizon Therapeutics — Investor Presentation (October 2026)
33 slides from Neurizon Therapeutics's investor presentation, Oct 7, 2026
Slide 1: Leadership Roundtable Webinar Reminder and Updated Investor Presentation
Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Neurizon Leadership Roundtable Webinar Reminder and Updated Investor Presentation For personal use only Highlights: Shareholders and interested investors are invited to join Neurizon’s Leadership Roundtable webinar featuring Neurizo
Slide 2: About Neurizon Therapeutics Limited
Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com About Neurizon Therapeutics Limited Neurizon Therapeutics Limited (ASX: NUZ) is a late clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candida
Slide 3: Advancing NUZ-001 in ALS towards a key clinical readout
rsonal use only Advancing NUZ-001 in ALS towards a key clinical readout Investor Presentation - October 2026 ABN 35 094 006 023
Slide 4: Disclaimer
Disclaimer This disclaimer applies to this presentation and the information contained in it (This presentation has Future Matters been prepared by Neurizon Therapeutics Limited (ASX: NUZ) (the “Company”)). It does not purport to contain all the information that a prospective investor may require in
Slide 5: Our Vision
Our Vision rsonal use only To lead the development of treatments towards a promising new horizon for people living with neurodegenerative diseases.
Slide 6: Neurizon: A late clinical-stage biotech developing therapies for neurodegenerative diseases
Neurizon: A late clinical-stage biotech developing therapies for neurodegenerative diseases Lead ALS/MND program in Phase 2/3, with topline results expected in late Q2 CY2027 rsonal use only LEAD ASSET: NUZ-001 Investigational oral small molecule being developed initially in ALS/MND and currently ev
Slide 7: Why look now
Why look now A randomised Phase 2/3 readout in late Q2 2027 is the next value inflection rsonal use only 1 2 Late Q2 2027 Clinical advancement Supply chain readiness for scale Expected topline from the 250- participant Phase 2/3 ALS trial. A 250-participant randomised Phase 2/3 Long-term supply agre
Slide 8: Leadership for the next stage
Leadership for the next stage Dr Chris Bremer commencing as Chief Executive Officer on 1 October 2026 rsonal use only CLINICAL DEVELOPMENT SCIENCE AND REGULATORY CHIEF EXECUTIVE OFFICER John Clark · Amanda Seiz Dr Martin Engel · Linda McBride Dr Chris Bremer · Dr Chris Freitag Effective 1 October 20
Slide 9: NUZ-001: from scientific origin to clinical execution
NUZ-001: from scientific origin to clinical execution From an established veterinary molecule to a randomised Phase 2/3 in ALS 2005 - 2023 2024 – 2025 NOW TO LATE Q2 2027 rsonal use only 1 2 3 Translation to human disease Clinical validation and Clinical execution and Neurizon formation HEALEY selec
Slide 10: About ALS
rsonal use only About ALS
Slide 11: ALS is a rapidly progressive neurodegenerative disease with significant unmet need
ALS is a rapidly progressive neurodegenerative disease with significant unmet need ALS contributes to progressive degeneration of motor neurons, ALS AT A GLANCE rsonal use only leading to increasing loss of voluntary muscle function SPEECH 2–5 YEARS ~90% Loss of ability to speak Typical life expecta
Slide 12: TDP-43 dysfunction & aggregation links ALS pathology to motor neuron failure
TDP-43 dysfunction & aggregation links ALS pathology to motor neuron failure In most ALS/MND, nuclear TDP-43 is lost and accumulates in the cytoplasm, disrupting RNA processing, axonal maintenance and communication with muscles rsonal use only TDP-43 IS LOST FROM THE NUCLEUS THE MOTOR NEURON–MUSCLE
Slide 13: ALS: high unmet need with significant value potential
ALS: high unmet need with significant value potential Three decades of approvals have delivered limited clinical benefit rsonal use only Current US ALS treatment landscape Key ALS Value Reference Point: Shionogi – RADICAVA (2026) 2017 IV 1995 2023 US$2.5B 2022 ORAL 4 RILUZOLE 1 RADICAVA® / RADICAVA
Slide 14: Science Behind NUZ-001
rsonal use only Science Behind NUZ-001
Slide 15: Therapeutic Approaches Addressing ALS Biology
Therapeutic Approaches Addressing ALS Biology rsonal use only Oxidative Stress Protein Homeostasis Neutralise toxic free radicals and Addressing cellular quality-control systems involved in clearing toxic protect vital cellular components. protein aggregates. Gene translation Neuroinflammation & Gen
Slide 16: Pre-clinical Evidence Supporting NUZ-001 Potential in ALS/MND
Pre-clinical Evidence Supporting NUZ-001 Potential in ALS/MND NUZ-001 Enhances Protein Clearance Pathways to Remove Toxic Protein Aggregates Enhances protein clearance rsonal use only mechanisms (autophagy & proteosomal system) Consistent effects Restores NfL axonal health observed across models: an
Slide 17: NUZ-001 Expansion potential: Platform Optionality for Proteinopathy-Driven Diseases
NUZ-001 Expansion potential : Platform Optionality for Proteinopathy-Driven Diseases Strong mechanistic rationale for potential efficacy across a wide array of neurodegenerative diseases. Impaired proteostasis rsonal use only contributes to the formation of intracellular inclusion bodies of misfolde
Slide 18: Clinical Development
rsonal use only Clinical Development
Slide 19: Phase 1b and Open Label Extension Study
Phase 1b and Open Label Extension Study Early Clinical Development of NUZ-001 in MND/ALS started in Australia rsonal use only Highlights (Based on a study population of n=12 patients) SLOWED FUNCTIONAL RESPIRATORY PRIMARY OUTCOME DECLINE STABILISATION • Long-term treatment with NUZ-001 at the • Sust
Slide 20: Phase 1b and Open Label Extension Results
Phase 1b and Open Label Extension Results Preliminary Signals of Efficacy in ALSFRS-R and SVC Treatment with NUZ-001 across combined Phase 1 and OLE studies slowed the progression of ALS in all patients by 31% for ALSFRS-R and 43% for SVC percent predicted (PP) when compared to matched controls from t
Slide 21: NUZ-001 shows improved survival vs matched controls
Phase 1b & Open Label Extension NUZ-001 shows improved survival vs matched controls rsonal use only NUZ-001 treatment resulted in statistically significantly longer survival of participants with ALS, (X2=11.35, p=0.00075), compared to matched controls1 from the PRO-ACT database2 Analysis* suggests t
Slide 22: Clinical development progress from Phase 1b to Phase 2/3
Clinical development progress from Phase 1b to Phase 2/3 Phase 1b established preliminary safety profile & informed the hypothesis; HEALEY is designed to provide the controlled evidence rsonal use only Phase 1b Foundation in 12 Clinical Questions to be HEALEY PROVIDES THE EVIDENCE People Living with
Slide 23: Regimen I is designed to investigate clinical benefit
Regimen I is designed to investigate clinical benefit REGIMEN I AT A GLANCE WHY THESE DESIGN CHOICES MATTER rsonal use only Design Double-blind, placebo-controlled adaptive Phase 2/3 under the HEALEY master protocol 36-week blinded period Participants 250 enrolled at close of recruitment (protocol e
Slide 24: Regimen I Biomarker Portfolio
Regimen I Biomarker Portfolio Connecting clinical response profile with biological measures provides development optionality rsonal use only Identify subgroups Support regulatory Blood / CSF dialogue response to disease and treatment Clarify who may benefit Add biological context most in a to HEALEY
Slide 25: Expanded access protocol extends NUZ-001 to patients outside Regimen I
Expanded access protocol extends NUZ-001 to patients outside Regimen I EAP is complementary to HEALEY RCT and fully funded by US National Institute of Health (NIH) rsonal use only What the program does Why it Why it matters matters HEALEY REGIMEN I (RCT) Access outside the trial ✓ Provides NUZ-001 t
Slide 26: The Road Ahead
rsonal use only The Road Ahead
Slide 27: Comparison of Key Outcomes Across Approved ALS Treatments & NUZ-001
Comparison of Key Outcomes Across Approved ALS Treatments & NUZ-001 Cross-trial comparisons are descriptive only; differences in study design, patient populations, and endpoints limit direct comparability. ALSFRS-R FVC/SVC Survival (Improvement (Improvement (Improvement Annual Sales rsonal use only
Slide 28: A Trial Pathway Built To Carry Advanced Regulatory Discussion
A Trial Pathway Built To Carry Advanced Regulatory Discussion UNDER WAY LATE Q2 CY2027 FOLLOWING READOUT SUBJECT TO DATA rsonal use only Blinded treatment Phase 2/3 readout Agency engagement Registration path Function, survival, respiratory, safety and 36-week randomised period, then an biomarker da
Slide 29: Cost and Capital Management
Cost and Capital Management Fully funded to pivotal top line readout out, with material non-dilutive funding Cost Management & Capital Funding Strategy — Three-Part Framework Funding Pillars rsonal use only Allocation EXISTING CASH BALANCE & R&D RECEIVABLE ↓ Non-clinical spend reduced COMPLETE Pre-c
Slide 30: A strong foundation set with Elanco ahead of topline
A strong foundation set with Elanco ahead of topline Embedded licence, supply and equity ties settle manufacturing and partnering before HEALEY readout ELANCO AGREEMENT IMPACT ON COMMERCIAL READINESS rsonal use only Exclusive global licence Freedom to commercialise or partner globally Worldwide righ
Slide 31: Major value inflection points expected in the near-term
Major value inflection points expected in the near-term Multiple material developments that change the investment case, converging soon rsonal use only Q4 CY2026 CY2027 Q2 CY2027 Late Q2 CY2027 Post-topline Expanding Pre- Expanded Access Trial completion and HEALEY topline Regulatory Clinical Eviden
Slide 32: Why Neurizon, why now
Why Neurizon, why now A defining randomised readout in late Q2 CY2027, with groundwork in place rsonal use only 1 A 250-participant randomised Phase 2/3 in ALS, efficiently run Late Q2 2 Record enrolment within the HEALEY platform, in under five months CY2027 3 Early clinical signals that shaped the
Slide 33: Thank You
rsonal use only Thank You Registered Address: Suite 2, Level 11, 385 Bourke Street Melbourne, VIC 3000 Australia +61 (3) 9692 7222 enquiries@neurizon.com
Neurizon Therapeutics — Investor Presentation (October 2026) on 6ix